ERBB2 and breast cancer: The advent of combined neoadjuvant chemo-immune therapy has revolutionized the treatment of human epidermal growth factor receptor 2 (HER2)-amplified early-stage breast cancer, achieving pathologic complete response (pCR) rates of up to ≥ 50% [1].